Mavenir Wins Award for Multi-G Open RAN Small Cell Solutions
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, is pleased to announce that it has won the Small Cell Forum Judges’ Choice award for its role in transforming mobile networks through its Multi-G Open RAN small cell solutions and its Mobile Network Operator (MNO) Open RAN neutral host integration.
- Multi-G Open RAN small cell solutions: Adding 2G/3G across a single unified RAN to support Multi-G radio access in 2020, Mavenir extended its Open Radio Access Network (Open RAN) capabilities across 2G, 3G, 4G and 5G to offer MNOs and enterprises a complete end-to-end, software-centric network proposition, spanning small cell radios to converged packet core to digital enablement solutions. This enables the move towards one network, rather than managing cost and complexity of several different networks. With a seamless, multi radio access technology (Multi-RAT) single RAN solution, MNOs and enterprises can achieve the benefits of advanced radio solutions across all layers, including incorporating legacy technology in Open RAN strategies, the ability to scale for more users over a longer range, and the potential to take advantage of spectrum for secure private network deployments.
- Open RAN neutral host Integration: Mavenir’s Open Virtualised Radio Access Network (Open vRAN) is enabling the industries’ first Neutral Host In-Building (NHIB) OpenRAN technology platform, which was fully tested with tier one MNOs. The technology platform is the first cloud-enabled solution that solves indoor mobile connectivity challenges by enabling the ability to host multiple networks using the same IT infrastructure, providing considerable cost savings for MNOs.
Presenting the award, Caroline Gabriel, Chair of Judges and Co-founder Rethink Research, said, “The judges selected Mavenir for the special Judges’ Choice award for a rich record of innovation in many aspects of the small cell platform. We felt that Mavenir’s contribution went beyond a single awards category and that the company’s impact on the small cell market will be even greater following the acquisition of ip.access, a founder member of the small cell community.”
The virtual awards took place at the Small Cells World Summit, on Thursday 13th May 2021.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210514005035/en/
Contact information
PR Contact Mavenir
Emmanuela Spiteri
PR@mavenir.com
Global PR
Kevin Taylor
KTaylor@GlobalResultsPR.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections21.11.2024 14:00:00 CET | Press Release
Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, is proud to announce the extension of funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. This funding will support the preclinical development of Debio 1453, a novel antibiotic specifically designed to combatNeisseria gonorrhoeaeinfections. In line with the Debiopharm’s vision to set a new standard for treating N. gonorrhoeae infections by developing antibiotics with targeted activity, while potentially avoiding microbiome dysbiosis, the newly awarded $5.76 million USD will facilitate the advancement of essential preclinical research, positioning Debio 1453 for clinical progression. With Debio 1453, Debiopharm aims to provide a potentially valuable addition to the current antibiotic armamentarium, as
PwC Opens Google Cloud AI Experience Zones to Feature Solutions Powered by Google Cloud’s Generative AI21.11.2024 14:00:00 CET | Press Release
PwC today announced the opening of its first Google Cloud AI Experience Zone at the firm’s US Acceleration Center in Bengaluru, India. It also announced additional, near-term planned openings of Google Cloud AI Experience Zones in Boston, MA and San Francisco, CA. At each, PwC will invite clients to get hands-on experience with existing, next-gen solutions, powered by Google Cloud’s AI technology, including Google Gemini models, Vertex AI and more. “We're thrilled to deepen our alliance with Google Cloud and harness its groundbreaking AI capabilities in this innovative space,” said Jason Ruge, Partner, US Google Cloud Alliance Leader, PwC US. “These Google Cloud AI Experience Zones will help showcase how PwC’s industry-specific solutions built on Google Cloud technology, including Vertex AI and Gemini, can revolutionize digital and business transformations for our customers.” PwC’s leading industry capabilities enable business model reinvention and help companies transform their busine
United States, China, and United Kingdom Lead the Global AI Ranking According to Stanford HAI’s Global AI Vibrancy Tool21.11.2024 14:00:00 CET | Press Release
The Stanford Institute for Human-Centered AI (HAI) AI Index today released its Global AI Vibrancy Tool which allows flexible comparisons of 36 countries based on 42 openly available AI-specific indicators. Comparisons between countries can be made using either absolute or per capita versions of the indicators and are supported by interactive visualizations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121006002/en/ Graphic: Stanford Institute for Human-Centered Artificial Intelligence (HAI) The Global AI Vibrancy Tool measures the strength of the AI ecosystems based on 8 pillars — research and development, responsible AI, economy, education, diversity, policy and governance, public opinion, and infrastructure — with indicators including AI journal publications, total AI private investment, AI legislation passed, and foundation model datasets. It is designed to empower policymakers, industry leaders, researchers, and the
Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity21.11.2024 14:00:00 CET | Press Release
Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, on its nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i, an ultra-long-acting injectable amylin analog, fully biased GLP-1 receptor agonist. In September, Metsera reported positive topline results from the clinical trial conducted at Altasciences’ facility, in which MET-097i demonstrated a 7.5% reduction in body weight from baseline at day 36 (one week after the final dose) and a 380-hour half-life. This work enabled Metsera to recently initiate a randomized 16-week Phase II trial of MET-097i. In addition to clinical conduct, Altasciences supported Metsera with its Proactive Drug Development solution, including nonclinical, bioanalysis, CRO and program management services for several additional therapeutic candidates. Over the past six months, Altascienc
From AI to Energy Optimization: Barilla and Plug and Play Recognize the Most Innovative Food-Tech Startups21.11.2024 14:00:00 CET | Press Release
Barilla and Plug and Play, the world's largest open innovation platform, have announced the four winning projects of Good Food Makers, a program launched in 2019 with the goal of stimulating the development of new sustainable food solutions. The winners will participate in an eight-week program, working closely with Barilla managers to develop and test new technologies, benefiting from the vision of a company that has been dedicated to producing good and high-quality food for 147 years. The winners of the four categories in the 2024 edition—AI for Consumer Insights, Tasty and Healthy, Energy Shift, and Smart Start: Operators Onboarding—are: Voxpopme: A UK-based startup that is revolutionizing qualitative feedback analysis using artificial intelligence. The platform enables quick and in-depth understanding of consumer opinions, analyzing video and text data to highlight specific customer needs. This helps businesses create products that align more closely with market expectations and es
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom